Recent developments in the management of herpes simplex virus infection in HIV-infected persons

Clinical Infectious Diseases

Volumn 39, Issue SUPPL. 5, 2004, Pages

  Bartlett, John G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; FAMCICLOVIR; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VALACICLOVIR; VIRUS ANTIBODY;

ANTIBODY SCREENING; DRUG CHOICE; DRUG EFFICACY; DRUG USE; EDITORIAL; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE; VIRUS TRANSMISSION;

ACYCLOVIR; ANTIVIRAL AGENTS; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV; HIV INFECTIONS; HUMANS; RECURRENCE; VALINE;

EID: 7444226305     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/422360     Document Type: Editorial

References (22)

1. Stein DS, Graham NM, Park LP, et al. The effect of the interaction of acyclovir with zidovudine on progression to AIDS and survival: analysis of data in the Multicenter AIDS Cohort Study. Ann Intern Med 1994; 121:100-8.
2. Centers for Disease Control and Prevention (CDC), Health Resources and Services Administration, National Institutes of Health, HIV Medicine Association of the Infectious Diseases Society of America. Incorporating HIV prevention into the medical care of persons living with HIV: recommendations of the CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2003; 52(RR-12):1-24.
3. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Recomm Rep 2002; 51(RR-6):1-78.
4. Ioannidis JP, Collier AC, Cooper DA, et al. Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis 1998; 178:349-59.
5. Schacker TW, Hu H, Koelle D, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. Ann Intern Med 1998; 128:21-8.
6. DeJesus E, Wald A, Warren T, et al. Valaciclovir for suppression of recurrent genital herpes in HIV-infected subjects. J Infect Dis 2003; 188:1009-16.
7. Conant MA, Schacker TW, Murphy RL, Gold J, Crutchfield LT, Crooks RJ, International Valaciclovir HSV Study Group. Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Int J STD AIDS 2002; 13:12-21.
8. Reynolds SJ, Risbud AR, Shepherd ME, et al. Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India. J Infect Dis 2003; 187:1509-12.
9. Koelle DM, Abbo H, Peck A, Ziegweld K, Corey L. Direct recovery of herpes simplex virus (HSV)-specific T lymphocyte clones from recurrent genital HSV-2 lesions. J Infect Dis 1994; 169:956-61.
10. Wald A, Zeh J, Selke S, Warren T, Ashley R, Corey L. Genital shedding of herpes simplex virus among men. J Infect Dis 2002; 186(Suppl 1):S34-9.
11. Koelle DM, Benedetti J, Langenberg A, Corey L. Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med 1992; 116:433-7.
12. Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995; 333:770-5.
13. Scoular A, Gillespie G, Carman WF. Polymerase chain reaction for diagnosis of genital herpes in a genitourinary medicine clinic. Sex Transm Infect 2002; 78:21-5.
14. Whitley RJ, Roisman B. Herpes simplex virus infections. Lancet 2001; 357:1513-8.
15. Mertz KJ, Trees D, Levine WC, et al. Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group. J Infect Dis 1998; 178:1795-8.
16. Chen C, Ballard R, Beck-Sague C, et al. Human immunodeficiency virus infection and genital ulcer disease in South Africa: the herpetic connection. Sex Transm Dis 2000; 27:21-9.
17. Wald A, Zeb J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000; 342:844-50.
18. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004; 350:11-20.
19. Wald A, Langenberg AG, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001; 285:3100-6.
20. Reyes M, Shaik NS, Graber JM, et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 2003; 163:76-80.
21. Wald A, Corey L. How does herpes simplex virus type 2 influence human immunodeficiency virus infection and pathogenesis? J Infect Dis 2003; 187:1509-12.
22. Schacker T, Ryncarz AJ, Goddard J, et al. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998; 280:61-6.